Search

Your search keyword '"Koopman, Miriam"' showing total 1,151 results
Start Over Author "Koopman, Miriam"
1,151 results on '"Koopman, Miriam"'

201. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care

Author

Derksen, Jeroen W.G., Vink, Geraldine R., Elferink, Marloes A.G., Roodhart, Jeanine M.L., Verkooijen, Helena M., Grevenstein, Wilhelmina M.U. van, Siersema, P.D., Wilt, J.H.W. de, May, Anne M., Koopman, Miriam, Derksen, Jeroen W.G., Vink, Geraldine R., Elferink, Marloes A.G., Roodhart, Jeanine M.L., Verkooijen, Helena M., Grevenstein, Wilhelmina M.U. van, Siersema, P.D., Wilt, J.H.W. de, May, Anne M., and Koopman, Miriam

Abstract

Contains fulltext : 235069.pdf (Publisher’s version ) (Open Access)

Published
2021

202. Disease recurrence after colorectal cancer surgery in the modern era:a population-based study

Author

Qaderi, Seyed M, Galjart, Boris, Verhoef, Cornelis, Slooter, Gerrit D, Koopman, Miriam, Verhoeven, Robert H A, de Wilt, Johannes H W, van Erning, Felice N, Qaderi, Seyed M, Galjart, Boris, Verhoef, Cornelis, Slooter, Gerrit D, Koopman, Miriam, Verhoeven, Robert H A, de Wilt, Johannes H W, and van Erning, Felice N

Abstract

PURPOSE: This population-based study determined the cumulative incidence (CI) of local, regional, and distant recurrences, examined metastatic patterns, and identified risk factors for recurrence after curative treatment for CRC.METHODS: All patients undergoing resection for pathological stage I-III CRC between January 2015 and July 2015 and registered in the Netherlands Cancer Registry were selected (N = 5412). Additional patient record review and data collection on recurrences was conducted by trained administrators in 2019. Three-year CI of recurrence was calculated according to sublocation (right-sided: RCC, left-sided: LCC and rectal cancer: RC) and stage. Cox competing risk regression analyses were used to identify risk factors for recurrence.RESULTS: The 3-year CI of recurrence for stage I, II, and III RCC and LCC was 0.03 vs. 0.03, 0.12 vs. 0.16, and 0.31 vs. 0.24, respectively. The 3-year CI of recurrence for stage I, II, and III RC was 0.08, 0.24, and 0.38. Distant metastases were found in 14, 12, and 16% of patients with RCC, LCC, and RC. Multiple site metastases were found often in patients with RCC, LCC, and RC (42 vs. 32 vs. 28%). Risk factors for recurrence in stage I-II CRC were age 65-74 years, pT4 tumor size, and poor tumor differentiation whereas in stage III CRC, these were ASA III, pT4 tumor size, N2, and poor tumor differentiation.CONCLUSIONS: Recurrence rates in recently treated patients with CRC were lower than reported in the literature and the metastatic pattern and recurrence risks varied between anatomical sublocations.

Published
2021

203. Colorectal cancer care and patients’ perceptions before and during COVID-19: implications for subsequent SARS-CoV-2 infection waves

Author

Derksen, Jeroen W G, May, Anne M, van de Poll-Franse, Lonneke V, De Rooij, Belle H, Hafkenscheid, Dorothee A, Verkooijen, Helena M, Koopman, Miriam, Vink, Geraldine R, Derksen, Jeroen W G, May, Anne M, van de Poll-Franse, Lonneke V, De Rooij, Belle H, Hafkenscheid, Dorothee A, Verkooijen, Helena M, Koopman, Miriam, and Vink, Geraldine R

Abstract

Background Changes in colorectal cancer (CRC) care planning because of the coronavirus disease 2019 (COVID-19) pandemic and associated health-related quality of life (HRQoL) and well-being of patients with CRC are unknown. We report changes in CRC care and patient-reported outcomes including HRQoL, distress, and loneliness during the first wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods In April 2020, 4984 patients included in the nationwide Prospective Dutch Colorectal Cancer cohort were invited to complete a COVID-19–specific questionnaire, together with the validated European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30), De Jong Gierveld, and Hospital Anxiety and Depression Scale. Clinical data were obtained from the Netherlands Cancer Registry. Scores were compared with the year prior to COVID-19 and with an age- and sex-matched control population during COVID-19. Results In total, 3247 (65.1%) patients responded between April and June 2020. Of the patients, 17% had canceled, postponed, or changed hospital visits to a telephone or video consult, and 5.3% had adjusted, postponed, or canceled treatment. Compared with controls, patients reported worse HRQoL but comparable distress and less social loneliness (patients = 21.2%; controls = 32.9%). Compared with pre–COVID-19, clinically meaningful deterioration of HRQoL was more prevalent in patients with changes in cancer care planning than in patients without changes. Prior to undergoing or currently undergoing treatment and infection worries were associated with lower HRQoL. Conclusions CRC patients reported equal anxiety and depression but worse HRQoL than the control population. Changes in care planning were associated with deterioration of HRQoL and increased anxiety. In case of 1 or more risk factors, health-care specialists should discuss (mental) health status and possible support during f

Published
2021

204. Trends in Use and Perceptions about Triplet Chemotherapy plus Bevacizumab for Metastatic Colorectal Cancer

Author

Van Nassau, Sietske C., Bond, Marinde J., Scheerman, Ilva, Van Breeschoten, Jesper, Kessels, Rob, Valkenburg-Van Iersel, Liselot B., Verheul, Henk M., Buffart, Tineke E., Mekenkamp, Leonie J., Lemmens, Valery E., Koopman, Miriam, Bol, Guus M., Van Nassau, Sietske C., Bond, Marinde J., Scheerman, Ilva, Van Breeschoten, Jesper, Kessels, Rob, Valkenburg-Van Iersel, Liselot B., Verheul, Henk M., Buffart, Tineke E., Mekenkamp, Leonie J., Lemmens, Valery E., Koopman, Miriam, and Bol, Guus M.

Abstract

Importance: Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC). However, the degree of implementation of FOLFOXIRI-B in daily practice is unknown. Objectives: To evaluate the current adoption rate of FOLFOXIRI-B in patients with mCRC and investigate the perspectives of medical oncologists toward this treatment option. Design, Setting, and Participants: This 1-week, multicenter, cross-sectional study in the Netherlands used a flash mob design, which facilitates ultrafast data generation (flash) through the engagement of numerous researchers (mob). During the study week (March 1-5, 2021), patient data were retrieved from electronic health records of 47 hospitals on patients with mCRC who were referred to a medical oncologist between November 1, 2020, and January 31, 2021. Interviews were simultaneously conducted with 101 medical oncologists from 52 hospitals who regularly treat patients with mCRC. Exposure: First-line systemic treatment as determined by the treating physician. Main Outcomes and Measures: The FOLFOXIRI-B prescription rate was the main outcome. Current practice was compared with prescription rates in 2015 to 2018. Eligibility for treatment with FOLFOXIRI-B was estimated. An exploratory outcome was medical oncologists' reported perspectives on FOLFOXIRI-B. Results: A total of 5948 patients in the Netherlands (median age [interquartile range], 66 [57-73] years; 3503 [59%] male; and 3712 [62%] with left-sided or rectal tumor) were treated with first-line systemic therapy for synchronous mCRC. A total of 282 patients with mCRC underwent systemic therapy during the study period (2021). Of these 282 patients, 199 (71%) were treated with intensive first-line therapy other than FOLFOXIRI-B, of whom 184 (65%) were treated with oxaliplatin doublets with or without bevacizumab; 14 (5%) with irinotecan do

Published
2021

205. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

Author

MS Medische Oncologie, Cancer, Yin, Jun, Dawood, Shaheenah, Cohen, Romain, Meyers, Jeff, Zalcberg, John, Yoshino, Takayuki, Seymour, Matthew, Maughan, Tim, Saltz, Leonard, Van Cutsem, Eric, Venook, Alan, Schmoll, Hans-Joachim, Goldberg, Richard, Hoff, Paulo, Hecht, J Randolph, Hurwitz, Herbert, Punt, Cornelis, Diaz Rubio, Eduard, Koopman, Miriam, Cremolini, Chiara, Heinemann, Volker, Tournigard, Christophe, Bokemeyer, Carsten, Fuchs, Charles, Tebbutt, Niall, Souglakos, John, Doulliard, Jean-Yves, Kabbinavar, Fairooz, Chibaudel, Benoist, de Gramont, Aimery, Shi, Qian, Grothey, Axel, Adams, Richard, MS Medische Oncologie, Cancer, Yin, Jun, Dawood, Shaheenah, Cohen, Romain, Meyers, Jeff, Zalcberg, John, Yoshino, Takayuki, Seymour, Matthew, Maughan, Tim, Saltz, Leonard, Van Cutsem, Eric, Venook, Alan, Schmoll, Hans-Joachim, Goldberg, Richard, Hoff, Paulo, Hecht, J Randolph, Hurwitz, Herbert, Punt, Cornelis, Diaz Rubio, Eduard, Koopman, Miriam, Cremolini, Chiara, Heinemann, Volker, Tournigard, Christophe, Bokemeyer, Carsten, Fuchs, Charles, Tebbutt, Niall, Souglakos, John, Doulliard, Jean-Yves, Kabbinavar, Fairooz, Chibaudel, Benoist, de Gramont, Aimery, Shi, Qian, Grothey, Axel, and Adams, Richard

Published
2021

206. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer

Author

Epi Kanker Team B, Cancer, Epi Kanker Team A, MS Medische Oncologie, Yin, Jun, Cohen, Romain, Jin, Zhaohui, Liu, Heshan, Pederson, Levi, Adams, Richard, Grothey, Axel, Maughan, Timothy S, Venook, Alan, Van Cutsem, Eric, Punt, Cornelis, Koopman, Miriam, Falcone, Alfredo, Tebbutt, Niall C, Seymour, Matthew T, Bokemeyer, Carsten, Rubio, Eduardo Diaz, Kaplan, Richard, Heinemann, Volker, Chibaudel, Benoist, Yoshino, Takayuki, Zalcberg, John, Andre, Thierry, De Gramont, Aimery, Shi, Qian, Lenz, Heinz-Josef, Epi Kanker Team B, Cancer, Epi Kanker Team A, MS Medische Oncologie, Yin, Jun, Cohen, Romain, Jin, Zhaohui, Liu, Heshan, Pederson, Levi, Adams, Richard, Grothey, Axel, Maughan, Timothy S, Venook, Alan, Van Cutsem, Eric, Punt, Cornelis, Koopman, Miriam, Falcone, Alfredo, Tebbutt, Niall C, Seymour, Matthew T, Bokemeyer, Carsten, Rubio, Eduardo Diaz, Kaplan, Richard, Heinemann, Volker, Chibaudel, Benoist, Yoshino, Takayuki, Zalcberg, John, Andre, Thierry, De Gramont, Aimery, Shi, Qian, and Lenz, Heinz-Josef

Published
2021

207. Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis

Author

Unit Opleiding Aios, MS Medische Oncologie, Cancer, Epi Kanker Team B, Epi Kanker Team A, Adams, Richard, Goey, Kaitlyn, Chibaudel, Benoist, Koopman, Miriam, Punt, Cornelis, Arnold, Dirk, Hinke, Axel, Hegewisch-Becker, Susanna, de Gramont, Aimery, Labianca, Roberto, Diaz Rubio, Eduardo, Magne Tveit, Kjell, Wasan, Harpreet, Kaplan, Richard, Brown, Louise, Maughan, Tim, Fisher, David, Unit Opleiding Aios, MS Medische Oncologie, Cancer, Epi Kanker Team B, Epi Kanker Team A, Adams, Richard, Goey, Kaitlyn, Chibaudel, Benoist, Koopman, Miriam, Punt, Cornelis, Arnold, Dirk, Hinke, Axel, Hegewisch-Becker, Susanna, de Gramont, Aimery, Labianca, Roberto, Diaz Rubio, Eduardo, Magne Tveit, Kjell, Wasan, Harpreet, Kaplan, Richard, Brown, Louise, Maughan, Tim, and Fisher, David

Published
2021

208. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers

Author

MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, Kunst, Natalia, van Erning, Felice N, Koopman, Miriam, Medema, Jan P, Vermeulen, Louis, Ijzermans, Jan N M, Vink, Geraldine R, Punt, Cornelis J A, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, Kunst, Natalia, van Erning, Felice N, Koopman, Miriam, Medema, Jan P, Vermeulen, Louis, Ijzermans, Jan N M, Vink, Geraldine R, Punt, Cornelis J A, and Coupé, Veerle M H

Published
2021

209. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database

Author

Epi Kanker Team B, Cancer, MS Medische Oncologie, Cohen, Romain, Liu, Heshan, Fiskum, Jack, Adams, Richard, Chibaudel, Benoist, Maughan, Timothy S, Van Cutsem, Eric, Venook, Alan, Douillard, Jean-Yves, Heinemann, Volker, Ja Punt, Cornelis, Falcone, Alfredo, Bokemeyer, Carsten, Kaplan, Richard, Lenz, Heinz-Josef, Koopman, Miriam, Yoshino, Takayuki, Zalcberg, John, Grothey, Alex, de Gramont, Aimery, Shi, Qian, André, Thierry, Epi Kanker Team B, Cancer, MS Medische Oncologie, Cohen, Romain, Liu, Heshan, Fiskum, Jack, Adams, Richard, Chibaudel, Benoist, Maughan, Timothy S, Van Cutsem, Eric, Venook, Alan, Douillard, Jean-Yves, Heinemann, Volker, Ja Punt, Cornelis, Falcone, Alfredo, Bokemeyer, Carsten, Kaplan, Richard, Lenz, Heinz-Josef, Koopman, Miriam, Yoshino, Takayuki, Zalcberg, John, Grothey, Alex, de Gramont, Aimery, Shi, Qian, and André, Thierry

Published
2021

210. Mismatch repair status in patient‐derived colorectal cancer organoids does not affect intrinsic tumor cell sensitivity to systemic therapy

Author

Lab Translational Oncology, Cancer, Onderzoek Medische Oncologie, Hubrecht Institute with UMC, MS Medische Oncologie, Regenerative Medicine and Stem Cells, Küçükköse, Emre, Wensink, G. Emerens, Roelse, Celine M., van Schelven, Susanne J., Raats, Daniëlle A.E., Boj, Sylvia F., Koopman, Miriam, Laoukili, Jamila, Roodhart, Jeanine M.L., Kranenburg, Onno, Lab Translational Oncology, Cancer, Onderzoek Medische Oncologie, Hubrecht Institute with UMC, MS Medische Oncologie, Regenerative Medicine and Stem Cells, Küçükköse, Emre, Wensink, G. Emerens, Roelse, Celine M., van Schelven, Susanne J., Raats, Daniëlle A.E., Boj, Sylvia F., Koopman, Miriam, Laoukili, Jamila, Roodhart, Jeanine M.L., and Kranenburg, Onno

Published
2021

211. Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer: A Population-Based Study

Author

Cancer, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, Brouwer, Nelleke PM, van der Kuil, Auke J S, Verhoeven, Rob H A, Elias, Sjoerd G, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, Brouwer, Nelleke PM, van der Kuil, Auke J S, Verhoeven, Rob H A, Elias, Sjoerd G, Vink, Geraldine R, Punt, Cornelis J A, de Wilt, Johannes H W, and Koopman, Miriam

Published
2021

212. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study

Author

MS Medische Oncologie, Cancer, Qaderi, Seyed M, Galjart, Boris, Verhoef, Cornelis, Slooter, Gerrit D, Koopman, Miriam, Verhoeven, Robert H A, de Wilt, Johannes H W, van Erning, Felice N, MS Medische Oncologie, Cancer, Qaderi, Seyed M, Galjart, Boris, Verhoef, Cornelis, Slooter, Gerrit D, Koopman, Miriam, Verhoeven, Robert H A, de Wilt, Johannes H W, and van Erning, Felice N

Published
2021

213. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial

Author

Arts Assistenten CTC, MS CGO, Cancer, MS Medische Oncologie, Cancer Center Patiëntenzorg, Lab Translational Oncology, Regenerative Medicine and Stem Cells, Rovers, Koen P., Bakkers, Checca, Nienhuijs, Simon W., Burger, Jacobus W.A., Creemers, Geert Jan M., Thijs, Anna M.J., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Van Meerten, Esther, Tuynman, Jurriaan B., Kusters, Miranda, Versteeg, Kathelijn S., Aalbers, Arend G.J., Kok, Niels F.M., Buffart, Tineke E., Wiezer, Marinus J., Boerma, Djamila, Los, Maartje, De Reuver, Philip R., Bremers, Andreas J.A., Verheul, Henk M.W., Kruijff, Schelto, De Groot, Derk Jan A., Witkamp, Arjen J., Van Grevenstein, Wilhelmina M.U., Koopman, Miriam, Nederend, Joost, Lahaye, Max J., Kranenburg, Onno, Fijneman, Remond J.A., Van 'T Erve, Iris, Snaebjornsson, Petur, Hemmer, Patrick H.J., Dijkgraaf, Marcel G.W., Punt, Cornelis J.A., Tanis, Pieter J., De Hingh, Ignace H.J.T., Arts Assistenten CTC, MS CGO, Cancer, MS Medische Oncologie, Cancer Center Patiëntenzorg, Lab Translational Oncology, Regenerative Medicine and Stem Cells, Rovers, Koen P., Bakkers, Checca, Nienhuijs, Simon W., Burger, Jacobus W.A., Creemers, Geert Jan M., Thijs, Anna M.J., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Van Meerten, Esther, Tuynman, Jurriaan B., Kusters, Miranda, Versteeg, Kathelijn S., Aalbers, Arend G.J., Kok, Niels F.M., Buffart, Tineke E., Wiezer, Marinus J., Boerma, Djamila, Los, Maartje, De Reuver, Philip R., Bremers, Andreas J.A., Verheul, Henk M.W., Kruijff, Schelto, De Groot, Derk Jan A., Witkamp, Arjen J., Van Grevenstein, Wilhelmina M.U., Koopman, Miriam, Nederend, Joost, Lahaye, Max J., Kranenburg, Onno, Fijneman, Remond J.A., Van 'T Erve, Iris, Snaebjornsson, Petur, Hemmer, Patrick H.J., Dijkgraaf, Marcel G.W., Punt, Cornelis J.A., Tanis, Pieter J., and De Hingh, Ignace H.J.T.

Published
2021

214. Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients

Author

Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, and Koopman, Miriam

Published
2021

215. Colorectal Cancer Care and Patients' Perceptions Before and During COVID-19: Implications for Subsequent SARS-CoV-2 Infection Waves

Author

Epi Kanker Team B, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Trialbureau Beeld, MS Medische Oncologie, Onderzoek Medische Oncologie, Derksen, Jeroen W G, May, Anne M, van de Poll-Franse, Lonneke V, de Rooij, Belle H, Hafkenscheid, Dorothee A, Verkooijen, Helena M, Koopman, Miriam, Vink, Geraldine R, Epi Kanker Team B, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Trialbureau Beeld, MS Medische Oncologie, Onderzoek Medische Oncologie, Derksen, Jeroen W G, May, Anne M, van de Poll-Franse, Lonneke V, de Rooij, Belle H, Hafkenscheid, Dorothee A, Verkooijen, Helena M, Koopman, Miriam, and Vink, Geraldine R

Published
2021

216. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients

Author

MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team A, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Koopman, Miriam, Vink, Geraldine R, Punt, Cornelis J A, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Onderzoek Medische Oncologie, Epi Kanker Team A, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Koopman, Miriam, Vink, Geraldine R, Punt, Cornelis J A, and Coupé, Veerle M H

Published
2021

217. Clinical outcomes of biliary drainage of malignant biliary obstruction due to colorectal cancer metastases: A systematic review

Author

Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, Lab Reumatologie/Klinische Immunologie, JC onderzoeksprogramma Methodologie, Infection & Immunity, MS Medische Oncologie, Kastelijn, Janine B, van der Loos, Maria Atc, Welsing, Paco Mj, Dhondt, Elisabeth, Koopman, Miriam, Moons, Leon Mg, Vleggaar, Frank P, Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, Lab Reumatologie/Klinische Immunologie, JC onderzoeksprogramma Methodologie, Infection & Immunity, MS Medische Oncologie, Kastelijn, Janine B, van der Loos, Maria Atc, Welsing, Paco Mj, Dhondt, Elisabeth, Koopman, Miriam, Moons, Leon Mg, and Vleggaar, Frank P

Published
2021

218. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Author

Onderzoek Medische Oncologie, Cancer, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Hubrecht Institute with UMC, Lab Translational Oncology, Regenerative Medicine and Stem Cells, Wensink, G Emerens, Elias, Sjoerd G, Mullenders, Jasper, Koopman, Miriam, Boj, Sylvia F, Kranenburg, Onno W, Roodhart, Jeanine M L, Onderzoek Medische Oncologie, Cancer, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Hubrecht Institute with UMC, Lab Translational Oncology, Regenerative Medicine and Stem Cells, Wensink, G Emerens, Elias, Sjoerd G, Mullenders, Jasper, Koopman, Miriam, Boj, Sylvia F, Kranenburg, Onno W, and Roodhart, Jeanine M L

Published
2021

219. Dose-Response and Dose-Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer

Author

Researchgr. Nucleaire Geneeskunde, Cancer, Arts-assistenten Radiologie, Onderzoek Beeld, MS Radiologie, Fysica Radiologie, MS Medische Oncologie, Other research (not in main researchprogram), Alsultan, Ahmed A, van Roekel, Caren, Barentsz, Maarten W, Smits, Maarten L J, Kunnen, Britt, Koopman, Miriam, Bruijnen, Rutger C G, de Keizer, Bart, Lam, Marnix G E H, Researchgr. Nucleaire Geneeskunde, Cancer, Arts-assistenten Radiologie, Onderzoek Beeld, MS Radiologie, Fysica Radiologie, MS Medische Oncologie, Other research (not in main researchprogram), Alsultan, Ahmed A, van Roekel, Caren, Barentsz, Maarten W, Smits, Maarten L J, Kunnen, Britt, Koopman, Miriam, Bruijnen, Rutger C G, de Keizer, Bart, and Lam, Marnix G E H

Published
2021

220. Longitudinal effects of adjuvant chemotherapy and related neuropathy on HU in stage II and III colon cancer patients: A prospective cohort study

Author

MS Medische Oncologie, Cancer, Epi Kanker Team A, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Twisk, Jos W R, Koopman, Miriam, Punt, Cornelis J A, Vink, Geraldine R, Coupé, Veerle M H, MS Medische Oncologie, Cancer, Epi Kanker Team A, Onderzoek Medische Oncologie, Jongeneel, Gabrielle, Greuter, Marjolein J E, van Erning, Felice N, Twisk, Jos W R, Koopman, Miriam, Punt, Cornelis J A, Vink, Geraldine R, and Coupé, Veerle M H

Published
2021

221. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research

Author

Onderzoek Medische Oncologie, Cancer, Epi Kanker Team B, Lab Translational Oncology, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Regenerative Medicine and Stem Cells, Wensink, Emerens, Bond, Marinde, Kucukkose, Emre, May, Anne, Vink, Geraldine, Koopman, Miriam, Kranenburg, Onno, Roodhart, Jeanine, Onderzoek Medische Oncologie, Cancer, Epi Kanker Team B, Lab Translational Oncology, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Regenerative Medicine and Stem Cells, Wensink, Emerens, Bond, Marinde, Kucukkose, Emre, May, Anne, Vink, Geraldine, Koopman, Miriam, Kranenburg, Onno, and Roodhart, Jeanine

Published
2021

222. Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis: Results of a Survey of Participants in the Dutch PROFILES Registry

Author

Epidemiology & Health Economics, Cancer, JC onderzoeksprogramma Kanker, Onderzoek Medische Oncologie, Studieteam Medische Oncologie, MS Medische Oncologie, van de Poll-Franse, Lonneke V, de Rooij, Belle H, Horevoorts, Nicole J E, May, Anne M, Vink, Geraldine R, Koopman, Miriam, van Laarhoven, Hanneke W M, Besselink, Marc G, Oerlemans, Simone, Husson, Olga, Beijer, Sandra, Ezendam, Nicole P M, Raijmakers, Natasja J H, Wollersheim, Barbara M, Hoedjes, Meeke, Siesling, Sabine, van Eenbergen, Mies C, Mols, Floortje, Epidemiology & Health Economics, Cancer, JC onderzoeksprogramma Kanker, Onderzoek Medische Oncologie, Studieteam Medische Oncologie, MS Medische Oncologie, van de Poll-Franse, Lonneke V, de Rooij, Belle H, Horevoorts, Nicole J E, May, Anne M, Vink, Geraldine R, Koopman, Miriam, van Laarhoven, Hanneke W M, Besselink, Marc G, Oerlemans, Simone, Husson, Olga, Beijer, Sandra, Ezendam, Nicole P M, Raijmakers, Natasja J H, Wollersheim, Barbara M, Hoedjes, Meeke, Siesling, Sabine, van Eenbergen, Mies C, and Mols, Floortje

Published
2021

223. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

Author

Verpleegafdeling Medische Oncologie, Onderzoek Medische Oncologie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Wensink, G Emerens, Elferink, Marloes A G, May, Anne M, Mol, Linda, Hamers, Patricia A H, Bakker, Sandra D, Creemers, Geert-Jan, de Groot, Jan Willem B, de Klerk, Gerty J, Haberkorn, Brigitte C M, Haringhuizen, Annebeth W, Hoekstra, Ronald, Hunting, J Cornelis B, Kerver, Emile D, Mathijssen-van Stein, Danielle, Polée, Marco B, Pruijt, Johannes F M, Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C, Simkens, Lieke H J, Tanis, Bea C, Ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L R, Tromp-van Driel, Cathrien S, Troost, Monique M, van de Wouw, Agnes J, van den Berkmortel, Franchette W P J, van der Pas, Anke J M, van der Velden, Ankie M T, van Dijk, Marjan A, van Dodewaard-de Jong, Joyce M, van Druten, Edith B, van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M W, Vestjens, Hanneke J H M J, Vincent, Jeroen, Kranenburg, Onno W, Punt, Cornelis J A, Vink, Geraldine R, Roodhart, Jeanine M L, Koopman, Miriam, Verpleegafdeling Medische Oncologie, Onderzoek Medische Oncologie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Wensink, G Emerens, Elferink, Marloes A G, May, Anne M, Mol, Linda, Hamers, Patricia A H, Bakker, Sandra D, Creemers, Geert-Jan, de Groot, Jan Willem B, de Klerk, Gerty J, Haberkorn, Brigitte C M, Haringhuizen, Annebeth W, Hoekstra, Ronald, Hunting, J Cornelis B, Kerver, Emile D, Mathijssen-van Stein, Danielle, Polée, Marco B, Pruijt, Johannes F M, Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C, Simkens, Lieke H J, Tanis, Bea C, Ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L R, Tromp-van Driel, Cathrien S, Troost, Monique M, van de Wouw, Agnes J, van den Berkmortel, Franchette W P J, van der Pas, Anke J M, van der Velden, Ankie M T, van Dijk, Marjan A, van Dodewaard-de Jong, Joyce M, van Druten, Edith B, van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M W, Vestjens, Hanneke J H M J, Vincent, Jeroen, Kranenburg, Onno W, Punt, Cornelis J A, Vink, Geraldine R, Roodhart, Jeanine M L, and Koopman, Miriam

Published
2021

227. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Author

Tol, Jolien, Koopman, Miriam, Cats, Annemieke, Rodenburg, Cees J., Creemers, Geert J.M., Schrama, Jolanda G., Erdkamp, Frans L.G., Vos, Allert H., van Groeningen, Cees J., Sinnige, Harm A.M., Richel, Dirk J., Voest, Emile E., Dijkstra, Jeroen R., Vink-Borger, Marianne E., Antonini, Ninja F., Mol, Linda, van Kriekan, Johan H.J.M., Dalesio, Otilia, and Punt, Cornelis J.A.

Subjects
Colorectal cancer -- Care and treatment, Chemotherapy -- Usage, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, Cancer -- Usage, Cancer -- Health aspects
Abstract

A study was conducted to evaluate the effect of addition of cetuximab to bevacizumab and chemotherapy in the treatment of metastatic colorectal cancer. Results indicated that the addition of cetuximab to the prescribed treatment resulted in a poorer quality of life and increased the risk of adverse effects among patients with colorectal cancer.

Published
2009

229. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Author

Goldberg, Richard M, Adams, Richard, Buyse, Marc, Eng, Cathy, Grothey, Axel, André, Thierry, Sobrero, Alberto F, Lichtman, Stuart M, Benson, Al B, Punt, Cornelis J A, Maughan, Tim, Burzykowski, Tomasz, Sommeijer, Dirkje, Saad, Everardo D, Shi, Qian, Coart, Elisabeth, Chibaudel, Benoist, Koopman, Miriam, Schmoll, Hans-Joachim, and Yoshino, Takayuki

Subjects
EXPERIMENTAL design, DATABASES, META-analysis, CLINICAL trials, COLORECTAL cancer, TREATMENT effectiveness, SECONDARY primary cancer, RESEARCH funding
Abstract

Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as discussed in this review. In oncology, the Aide et Recherche en Cancérologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-analysis in methodological research. The ARCAD database contains IPD from more than 38 000 patients enrolled in 46 studies and continues to collect phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly, we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

232. Dose–Response and Dose–Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer

Author

Alsultan, Ahmed A., primary, van Roekel, Caren, additional, Barentsz, Maarten W., additional, Smits, Maarten L.J., additional, Kunnen, Britt, additional, Koopman, Miriam, additional, Braat, Arthur J.A.T., additional, Bruijnen, Rutger C.G., additional, de Keizer, Bart, additional, and Lam, Marnix G.E.H., additional

Published
2021
Full Text
View/download PDF

233. BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database

Author

Cohen, Romain, primary, Liu, Heshan, additional, Fiskum, Jack, additional, Adams, Richard, additional, Chibaudel, Benoist, additional, Maughan, Timothy S, additional, Van Cutsem, Eric, additional, Venook, Alan, additional, Douillard, Jean-Yves, additional, Heinemann, Volker, additional, Ja Punt, Cornelis, additional, Falcone, Alfredo, additional, Bokemeyer, Carsten, additional, Kaplan, Richard, additional, Lenz, Heinz-Josef, additional, Koopman, Miriam, additional, Yoshino, Takayuki, additional, Zalcberg, John, additional, Grothey, Alex, additional, de Gramont, Aimery, additional, Shi, Qian, additional, and André, Thierry, additional

Published
2021
Full Text
View/download PDF

235. Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework: A Quantitative Modeling Framework

Author

Netterberg, Ida, Karlsson, Mats O., Terstappen, Leon W. M. M., Koopman, Miriam, Punt, Cornelis J. A., Friberg, Lena E., Oncology, and CCA - Imaging and biomarkers

Subjects
digestive system diseases
Abstract

Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS. Experimental Design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase III study (CAIRO2). Results: A tumor size model of tumor quiescence and drug resistance was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). Tumor size changes did not contribute additional predictive value when the mean CTC count was a predictor of OS. Treatment reduced the typical mean count from 1.43 to 0.477 (HR ¼ 3.94). The modeling framework was applied to explore whether dose modifications (increased and reduced) would result in a CTC count below 1/7.5 mL after 1 to 2 weeks of treatment. Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size was connected to CTC, its link to OS was weaker.

Published
2020

236. Circulating tumor cells, tumor- and endothelium- derived extracellular vesicles, but not circulating endothelial cells associate with poor prognosis in colorectal cancer

Author

Nanou, Afroditi, Mol, Linda, Koopman, Miriam, Punt, Cornelis J.A., Terstappen, L.W.M.M., Medical Cell Biophysics, and TechMed Centre

Abstract

Elevated tumor-derived EV (tdEV) and Circulating Tumor Cell (CTC) load in patients with metastatic cancer is associated with poor clinical outcome. In this study, we investigated whether endothelium-derived extracellular vesicles (edEVs) can be detected in the blood of metastatic colorectal cancer (mCRC) patients and whether there is an association with prognosis. The open-source ACCEPT software was used to enumerate edEVs, tdEVs and other objects from digitally stored CellSearch® images obtained after Circulating Endothelial Cell (CEC) and CTC enrichment from blood of 395 mCRC patients, before the initiation of a new therapy. Patients had participated in the prospective phase III CAIRO2 study. ACCEPT classified objects, CTC and CEC counts and patient information were used in univariable and multivariable analysis to determine their relation with Progression-Free Survival (PFS) and Overall Survival (OS). edEVs are present in blood of mCRC patients at 5-10 fold higher frequencies than CECs. A significantly shorter PFS and OS was observed for patients with ≥ 3 CTCs/ 7.5 mL, ≥ 40 tdEVs/ 7.5 mL and ≥ 287 edEVs/ 4.0 mL. The Hazard Ratio HR (95% CI) of PFS for increased CTCs, tdEVs and edEVs was 1.4 (1.1-1.9), 2.0 (1.5-2.6) and 1.7 (1.2-2.5), respectively. Similarly, the HR of OS for increased CTCs, tdEVs and edEVs was 2.2 (1.7-3.0), 2.7 (2.0-3.5) and 2.1 (1.5-2.8), respectively. There was no cut-off value for CECs leading to a dichotomization of patients with a significant HR. Both tdEVs and edEVs remained significant predictors of OS in multivariable analysis. edEVs and tdEVs are independent prognostic factors for OS in mCRC patients.

Published
2020

238. Additional file 2 of Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

Author

Franken, Mira D., Hond, Anne De, Degeling, Koen, Punt, Cornelis J. A., Koopman, Miriam, Groot, Carin A. Uyl-De, Versteegh, Matthijs M., and Oijen, Martijn G. H. Van

Abstract

Additional file 2: Table 1. Ordered logit regression (model 4) results for QLQ-C30 domain scores on EQ-5D-3L domain. Table 2. Ordered logit regression (model 4) results for QLQ-C30 domain scores on EQ-5D-3L domain. Table 3. Ordered logit regression (model 4) results for QLQ-C30 domain scores on EQ-5D-3L domain. Table 4. Separate equations subgroup approach (model 6) results for QLQ-C30 domain scores on EQ-5D-3L utility of i)

Published
2020
Full Text
View/download PDF

239. Additional file 4 of Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

Author

Franken, Mira D., Hond, Anne De, Degeling, Koen, Punt, Cornelis J. A., Koopman, Miriam, Groot, Carin A. Uyl-De, Versteegh, Matthijs M., and Oijen, Martijn G. H. Van

Abstract

Additional file 4: Figure 2. Predicted EQ-5D-3L utility versus the observed utility for a) the RE model with QLQ-C30 domain scores (preferred model 1); b) the RE model with continuous QLQ-C30 questions (model 2); c) the RE model with QLQ-C30 dummy questions (model 3); d) the ordered logit model on the EQ-5D-3L domains (model 4); e) beta regerssion (model 5) and; f) the separate equations subgroup approach (model 6). Figure 3. Prediction error (observed – predicted EQ-5D-3L uility) for a) the RE model with QLQ-C30 domain scores (preferred model 1); b) the RE model with continuous QLQ-C30 questions (model 2); c) the RE model with QLQ-C30 dummy questions (model 3); d) the ordered logit model on the EQ-5D-3L domains (model 4); e) beta regerssion(model 5) and; f) the separate equations subgroup approach (model 6).

Published
2020
Full Text
View/download PDF

240. Additional file 3 of Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

Author

Franken, Mira D., Hond, Anne De, Degeling, Koen, Punt, Cornelis J. A., Koopman, Miriam, Groot, Carin A. Uyl-De, Versteegh, Matthijs M., and Oijen, Martijn G. H. Van

Abstract

Additional file 3. Patient characteristics for concurently collected EQ-5D and partially incomplete QLQ-C30 questionnaires for which functional scale scores could still be calcuated.

Published
2020
Full Text
View/download PDF

241. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Author

Koopman, Miriam, Antonini, Ninja F, Douma, Joep, Wals, Jaap, Honkoop, Aafke H, Erdkamp, Frans LG, de Jong, Robert S, Rodenburg, Cees J, Vreugdenhil, Gerard, Loosveld, Olaf JL, van Bochove, Aart, Sinnige, Harm AM, Creemers, Geert-Jan M, Tesselaar, Margot ET, Slee, Peter H Th J, Werter, Marjon JBP, Mol, Linda, Dalesio, Otilia, and Punt, Cornelis JA

Published
2007
Full Text
View/download PDF

243. European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment

Author

Derksen, Jeroen W. G., Warren, Graham W., Jordan, Karin, Rauh, Stefan, Vera Garcia, Ruth, O'Mahony, Deirdre, Ahmed, Samreen, Vuylsteke, Peter, Radulovic, Sinisa, Tsoukalas, Nikolaos, Wysocki, Piotr J., Borner, Markus, Cesas, Alvydas, Elme, Anneli, Minn, Heikki, Ullenhag, Gustav J., Roodhart, Jeanine M. L., Koopman, Miriam, May, Anne M., Derksen, Jeroen W. G., Warren, Graham W., Jordan, Karin, Rauh, Stefan, Vera Garcia, Ruth, O'Mahony, Deirdre, Ahmed, Samreen, Vuylsteke, Peter, Radulovic, Sinisa, Tsoukalas, Nikolaos, Wysocki, Piotr J., Borner, Markus, Cesas, Alvydas, Elme, Anneli, Minn, Heikki, Ullenhag, Gustav J., Roodhart, Jeanine M. L., Koopman, Miriam, and May, Anne M.

Abstract

Background: Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns, but differences between the curative and palliative settings have not been described. We aimed to study the oncologist's perceptions on patients' tobacco use, current practices and barriers to providing smoking cessation support, while distinguishing between treatment with curative (C) and palliative (P) intent. Methods: In 2019, an online 34-item survey was sent to approximately 6235 oncologists from 16 European countries. Responses were descriptively reported and compared by treatment setting. Results: Responses from 544 oncologists were included. Oncologists appeared to favour addressing tobacco in the curative setting more than in the palliative setting. Oncologists believe that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation support should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C: 93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)–39% (C) routinely discuss medication options, and only 18% (P)–31% (C) provide cessation support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative settings (p < 0.001), but dominant barriers of time, resources, education and patient resistance were similar between settings. Conclusion: Oncologists appear to favour addressing tobacco use more in the curative setting; however, they discuss medication options and/or provide cessation support in a minority of cases. All patients who report current smoking should have access to evidence-based smoking cessation support, also patients treated with palliative intent given their increasing survival.

Published
2020
Full Text
View/download PDF

244. Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival : A Quantitative Modeling Framework

Author

Netterberg, Ida, Karlsson, Mats, Terstappen, Leon W. M. M., Koopman, Miriam, Punt, Cornelis J. A., Friberg, Lena, Netterberg, Ida, Karlsson, Mats, Terstappen, Leon W. M. M., Koopman, Miriam, Punt, Cornelis J. A., and Friberg, Lena

Abstract

Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS. Experimental Design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase III study (CAIRO2). Results: A tumor size model of tumor quiescence and drug resistance was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). Tumor size changes did not contribute additional predictive value when themean CTC count was a predictor of OS. Treatment reduced the typical mean count from 1.43 to 0.477 (HR = 3.94). The modeling framework was applied to explore whether dose modifications (increased and reduced) would result in a CTC count below 1/7.5 mL after 1 to 2 weeks of treatment. Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size was connected to CTC, its link to OS was weaker.

Published
2020
Full Text
View/download PDF

245. Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)

Author

Medicina, Medikuntza, Jongeneel, Gabrielle, Greuter, Marjolein J. E., Van Erning, Felice N., Koopman, Miriam, Medema, Jan P., Kandimalla, Raju, Goel, Ajay, Bujanda Fernández de Pierola, Luis, Meijer, Gerrit A., Fijneman, Remond J. A., Van Oijen, Martijn G. H., Ijzermans, Jan, Punt, Cornelis J. A., Vink, Geraldine R., Coupé, Veerle M. H., Medicina, Medikuntza, Jongeneel, Gabrielle, Greuter, Marjolein J. E., Van Erning, Felice N., Koopman, Miriam, Medema, Jan P., Kandimalla, Raju, Goel, Ajay, Bujanda Fernández de Pierola, Luis, Meijer, Gerrit A., Fijneman, Remond J. A., Van Oijen, Martijn G. H., Ijzermans, Jan, Punt, Cornelis J. A., Vink, Geraldine R., and Coupé, Veerle M. H.

Abstract

Aim To develop a decision model for the population-level evaluation of strategies to improve the selection of stage II colon cancer (CC) patients who benefit from adjuvant chemotherapy. Methods A Markov cohort model with a one-month cycle length and a lifelong time horizon was developed. Five health states were included; diagnosis, 90-day mortality, death other causes, recurrence and CC death. Data from the Netherlands Cancer Registry were used to parameterize the model. Transition probabilities were estimated using parametric survival models including relevant clinical and pathological covariates. Subsequently, biomarker status was implemented using external data. Treatment effect was incorporated using pooled trial data. Model development, data sources used, parameter estimation, and internal and external validation are described in detail. To illustrate the use of the model, three example strategies were evaluated in which allocation of treatment was based on (A) 100% adherence to the Dutch guidelines, (B) observed adherence to guideline recommendations and (C) a biomarker-driven strategy. Results Overall, the model showed good internal and external validity. Age, tumor growth, tumor sidedness, evaluated lymph nodes, and biomarker status were included as covariates. For the example strategies, the model predicted 83, 87 and 77 CC deaths after 5 years in a cohort of 1000 patients for strategies A, B and C, respectively. Conclusion This model can be used to evaluate strategies for the allocation of adjuvant chemotherapy in stage II CC patients. In future studies, the model will be used to estimate population-level long-term health gain and cost-effectiveness of biomarker-based selection strategies.

Published
2020

246. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer : Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

247. European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Derksen, Jeroen W G, Warren, Graham W, Jordan, Karin, Rauh, Stefan, Vera García, Ruth, O'Mahony, Deirdre, Ahmed, Samreen, Vuylsteke, Peter, Radulovic, Sinisa, Tsoukalas, Nikolaos, Wysocki, Piotr J, Borner, Markus, Cesas, Alvydas, Elme, Anneli, Minn, Heikki, Ullenhag, Gustav J, Roodhart, Jeanine M L, Koopman, Miriam, May, Anne M, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Derksen, Jeroen W G, Warren, Graham W, Jordan, Karin, Rauh, Stefan, Vera García, Ruth, O'Mahony, Deirdre, Ahmed, Samreen, Vuylsteke, Peter, Radulovic, Sinisa, Tsoukalas, Nikolaos, Wysocki, Piotr J, Borner, Markus, Cesas, Alvydas, Elme, Anneli, Minn, Heikki, Ullenhag, Gustav J, Roodhart, Jeanine M L, Koopman, Miriam, and May, Anne M

Abstract

BACKGROUND: Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns, but differences between the curative and palliative settings have not been described. We aimed to study the oncologist's perceptions on patients' tobacco use, current practices and barriers to providing smoking cessation support, while distinguishing between treatment with curative (C) and palliative (P) intent. METHODS: In 2019, an online 34-item survey was sent to approximately 6235 oncologists from 16 European countries. Responses were descriptively reported and compared by treatment setting. RESULTS: Responses from 544 oncologists were included. Oncologists appeared to favour addressing tobacco in the curative setting more than in the palliative setting. Oncologists believe that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation support should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C: 93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)-39% (C) routinely discuss medication options, and only 18% (P)-31% (C) provide cessation support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative settings (p < 0.001), but dominant barriers of time, resources, education and patient resistance were similar between settings. CONCLUSION: Oncologists appear to favour addressing tobacco use more in the curative setting; however, they discuss medication options and/or provide cessation support in a minority of cases. All patients who report current smoking should have access to evidence-based smoking cessation support, also patients treated with palliative intent given their increasing survival.

Published
2020

248. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

249. Health Economic Models for Metastatic Colorectal Cancer:A Methodological Review

Author

Degeling, Koen, Vu, Martin, Koffijberg, Hendrik, Wong, Hui Li, Koopman, Miriam, Gibbs, Peter, IJzerman, Maarten, Degeling, Koen, Vu, Martin, Koffijberg, Hendrik, Wong, Hui Li, Koopman, Miriam, Gibbs, Peter, and IJzerman, Maarten

Abstract

Objective: The aim of this systematic review was to provide a comprehensive and detailed review of structural and methodological assumptions in model-based cost-effectiveness analyses of systemic metastatic colorectal cancer (mCRC) treatments, and discuss their potential impact on health economic outcome estimates. Methods: Five databases (EMBASE, MEDLINE, Cochrane Library, Health Technology Assessment and National Health Service Health Economic Evaluation Database) were searched on 26 August 2019 for model-based full health economic evaluations of systemic mCRC treatment using a combination of free-text terms and subject headings. Full-text publications in English were eligible for inclusion if they were published in or after the year 2000. The Consolidated Health Economic Evaluation Reporting Standards checklist was used to assess the reporting quality of included publications. Study selection, appraisal and data extraction were performed by two reviewers independently. Results: The search yielded 1418 publications, of which 54 were included, representing 51 unique studies. Most studies focused on first-line treatment (n = 29, 57%), followed by third-line treatment (n = 13, 25%). Model structures were health-state driven (n = 27, 53%), treatment driven (n = 19, 37%), or a combination (n = 5, 10%). Cohort-level state-transition modelling (STM) was the most common technique (n = 33, 65%), followed by patient-level STM and partitioned survival analysis (both n = 6, 12%). Only 15 studies (29%) reported some sort of model validation. Health economic outcomes for specific strategies differed substantially between studies. For example, survival following first-line treatment with fluorouracil, leucovorin and oxaliplatin ranged from 1.21 to 7.33 years, with treatment costs ranging from US$8125 to US$126,606. Conclusions: Model-based cost-effectiveness analyses of systemic mCRC treatments have adopted varied modelling methods and structures, resulting in substantially d

Published
2020

250. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

Author

Onderzoek Medische Oncologie, Cancer, MS Medische Oncologie, Brouwer, Nelleke P M, van der Kruijssen, Dave E W, Hugen, Niek, de Hingh, Ignace H J T, Nagtegaal, Iris D, Verhoeven, Rob H A, Koopman, Miriam, de Wilt, Johannes H W, Onderzoek Medische Oncologie, Cancer, MS Medische Oncologie, Brouwer, Nelleke P M, van der Kruijssen, Dave E W, Hugen, Niek, de Hingh, Ignace H J T, Nagtegaal, Iris D, Verhoeven, Rob H A, Koopman, Miriam, and de Wilt, Johannes H W

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results